Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1386]

Cancer care in developing countries

Prof Ian Magrath - International Network for Cancer Treatment and Research...

Cancer care in developing countries ( Prof Ian Magrath - International Network for Cancer Treatment and Research, Brussels, Belgium )

Treatment options in castration-resistant prostate cancer: Expert discussion

Prof Karim Fizazi, Prof Eleni Efstathiou, Dr Bertrand Tombal and Prof Stephane...

Treatment options in castration-resistant prostate cancer: Expert discussion ( Prof Karim Fizazi, Prof Eleni Efstathiou, Dr Bertrand Tombal and Prof Stephane Oudard )

Dabrafenib plus trametinib preferable to vemurafenib alone in melanoma

Dr Caroline Robert - Gustave Roussy, Villejuif, France

Dabrafenib plus trametinib preferable to vemurafenib alone in melanoma ( Dr Caroline Robert - Gustave Roussy, Villejuif, France )

Nivolumab potentially superior to standard chemo in advanced melanoma

Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA

Nivolumab potentially superior to standard chemo in advanced melanoma ( Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA )

Targeted therapy for iodine-refractory thyroid cancer

Dr Makoto Tahara - National Cancer Center Hospital East, Kashiwa, Japan

$Targeted therapy for iodine-refractory thyroid cancer ( Dr Makoto Tahara - National Cancer Center Hospital East, Kashiwa, Japan )$

Questions raised about the future of lung cancer vaccination?

Prof Johan Vansteenkiste - University Hospital Leuven, Leuven, Belgium

Questions raised about the future of lung cancer vaccination? ( Prof Johan Vansteenkiste - University Hospital Leuven, Leuven, Belgium )

PD-L1 protein a possible immunotherapy target in mesothelioma

Prof Rolf Stahel - University Hospital of Zurich, Zurich, Switzerland

PD-L1 protein a possible immunotherapy target in mesothelioma ( Prof Rolf Stahel - University Hospital of Zurich, Zurich, Switzerland )

Improved response rate and survival with dabrafenib plus trametinib versus...

Dr Caroline Robert - Gustave Roussy, Villejuif, France

Improved response rate and survival with dabrafenib plus trametinib versus vemurafenib alone in melanoma ( Dr Caroline Robert - Gustave Roussy, Villejuif, France )

Vemurafenib plus cobimetinib achieves significant progression-free survival in...

Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia

Vemurafenib plus cobimetinib achieves significant progression-free survival in melanoma ( Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia )

Nivolumab shows signs of superior response rate compared to standard chemo in...

Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA

Nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma ( Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA )

Molecular targeting in cancer and the impact on personalised medicine

Prof Christian Dittrich - Ludwig Boltzmann Institute for Applied Cancer...

Molecular targeting in cancer and the impact on personalised medicine ( Prof Christian Dittrich - Ludwig Boltzmann Institute for Applied Cancer Research, Vienna, Austria )

Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for...

Dr Sandra Swain - Washington Cancer Institute, Washington, USA

Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer ( Dr Sandra Swain - Washington Cancer Institute, Washington, USA )

More from ecancer